Ratios Reveal: Breaking Down Lyell Immunopharma Inc (LYEL)’s Financial Health

Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Lyell Immunopharma Inc (NASDAQ: LYEL) closed the day trading at $0.95 up 3.64% from the previous closing price of $0.92. In other words, the price has increased by $3.64 from its previous closing price. On the day, 1.01 million shares were traded. LYEL stock price reached its highest trading level at $0.9831 during the session, while it also had its lowest trading level at $0.9.

Ratios:

For a better understanding of LYEL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.43 and its Current Ratio is at 13.43. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on October 30, 2024, Downgraded its rating to Underperform and sets its target price to $1 from $6 previously.

On June 27, 2024, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $6 to $1.

JP Morgan Downgraded its Overweight to Neutral on August 28, 2023, whereas the target price for the stock was revised from $15 to $5.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LYEL now has a Market Capitalization of 265259936 and an Enterprise Value of -116712416. For the stock, the TTM Price-to-Sale (P/S) ratio is 4582.10 while its Price-to-Book (P/B) ratio in mrq is 0.46. Its current Enterprise Value per Revenue stands at -1852.578 whereas that against EBITDA is 0.594.

Stock Price History:

Over the past 52 weeks, LYEL has reached a high of $3.26, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is -20.40%, while the 200-Day Moving Average is calculated to be -47.90%.

Shares Statistics:

Over the past 3-months, LYEL traded about 1.19M shares per day on average, while over the past 10 days, LYEL traded about 1378650 shares per day. A total of 253.96M shares are outstanding, with a floating share count of 125.06M. Insiders hold about 55.21% of the company’s shares, while institutions hold 22.58% stake in the company. Shares short for LYEL as of 1730332800 were 11138482 with a Short Ratio of 9.40, compared to 1727654400 on 10657278. Therefore, it implies a Short% of Shares Outstanding of 11138482 and a Short% of Float of 6.15.

Most Popular